RT Journal Article
SR Electronic
T1 Clinical evaluation of a RT-LAMP SARS-CoV-2 test for the Point-Of-Care, rapid, low-cost, integrating sample solid phase extraction and on which reagents are lyophilized
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.03.21264480
DO 10.1101/2021.10.03.21264480
A1 Coz, E.
A1 Garneret, P.
A1 Martin, E.
A1 do Nascimento, D. F.
A1 Vilquin, A.
A1 Hoinard, D.
A1 Feher, M.
A1 Grassin, Q.
A1 Vanhomwegen, J.
A1 Manuguerra, J.C
A1 Mukherjee, S.
A1 Olivo-Marin, J.-C.
A1 Brient-Litzler, E.
A1 Merzoug, M.
A1 Collin, E.
A1 Tabeling, P.
A1 Rossi, B.
YR 2021
UL http://medrxiv.org/content/early/2021/10/04/2021.10.03.21264480.abstract
AB Objectives Determine the sensitivity and specificity of a Point-Of-Care test (‘COVIDISC’) for SARS-COV2. The novelty of the test is to integrate, on the same (low-cost) compact plastic/paper device, solid phase RNA extraction and RT-LAMP amplification, all reagents being freeze-dried on it.Method Retrospective study with a cohort of 99 patients characterized by real-time RT-PCR. The 37 positive naso-pharyngeal samples cover a broad range of viral loads (from 5 gc /µL to 2 106 gc/ µL of sample).Results The COVIDISC found 36 positives (out of 37 by IP4 RT-PCR protocols) and 63 negatives (out of 62 by RT-PCR).Conclusion The sensitivity of the COVIDISC, found in this 99-patient retrospective study, is 97% and the specificity 100%.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialIRB00003888Funding StatementThe authors thank La Ville de Paris, ESPCI, CNRS, PSL, its Department of Tech Transfer PSL Valorisation, IPGG platform (ANR-10-EQPX-34), the Institut Pasteur, the Institut Carnot Pasteur Maladies Infectieuses (ANR-11-CARN-017-01), the Region Ile-de-France DIM ELICIT program, the Labex IBEID (ANR-10-LABX-62-IBEID), the France BioImaging infrastructure (ANR-10-INBS-04), ANR Flash, Fonds ESPCI, Bettencourt Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by National Institute of Health and Medical Research (INSERM) Ethics Evaluation Committee, the Institutional Review Board (IRB00003888).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data we refer to is included in the paper and in the references.